Insight Molecular Diagnostics Inc.

NASDAQ:IMDX

Medical - Diagnostics & Research

Healthcare
$1.59 +2.44%

+$0.13 today

Market cap
$52.08M
Beta
1.79
P/E (TTM)
-3.9
EPS (TTM)
-$1.39
52W Low $2.33High $8.51

Volume 0.64M

Average 0.38M

IMDX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Insight Molecular Diagnostics Inc.NASDAQ: IMDX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 34.52M shares rose 34.3% year over year, behind the +85.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 13.3% from the prior quarter. Over 3 fiscal years it compounded at +76.5% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +34.3% toward the trailing-twelve-month pace of +85.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
34.52M+13.3% QoQ
Last fiscal yearDec 2025
30.48M+133.2% YoY
LTMMar 2026
32.26M+85.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+34.3%——
1 year+133.2%——
3-year CAGR+76.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
30.48M USD
Year-over-year change
+133.2%
4-year CAGR
+61.8%

Weighted Avg Shares (Diluted) vs competitors

How IMDX compares with its peers on the latest reported figures

  • IMDX's LTM Mar 2026 weighted avg shares (diluted) of 32.26M shares is the lowest of the 10 companies compared; the peer median is 89.33M shares.
  • Its year-over-year change of +85.3% is the highest of 10, against a peer median of +16.7%.
  • Over three fiscal years its annual growth of +76.5% compares with a peer median of +17.6%.
IMDX Competitors Peer median
Weighted Avg Shares (Diluted) for IMDX and competitors
Company Period LTM YoY 3-year CAGR
SGMOSangamo Therapeutics, Inc.LTM Mar 2026322.14M +51.8%+22.0%
IVVDInvivyd, Inc.LTM Mar 2026193.02M +61.8%+16.7%
OABIOmniAb, Inc.LTM Mar 2026119.25M +15.1%+10.0%
CCCCC4 Therapeutics, Inc.LTM Mar 202696.61M +38.1%+19.3%
CDXSCodexis, Inc.LTM Mar 202689.33M +16.7%+10.1%
MISTMilestone Pharmaceuticals Inc.LTM Mar 202686.73M +33.0%+25.5%
PRLDPrelude Therapeutics IncorporatedLTM Mar 202674.4M -1.9%+17.6%
PEPGPepGen Inc.LTM Mar 202637.49M +15.0%+39.2%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 202636.32M -23.4%+1.9%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 202632.26M +85.3%+76.5%
Peer median (excluding IMDX) 89.33M+16.7%+17.6%

Competitors are the stored peer set for IMDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.2M958K1.5M1.88M4.06M
Cost of Revenue778K976K1.09M1.14M3.87M
Gross Profit1.42M(18K)413K740K190K
Gross Margin64.6%-1.9%27.5%39.3%4.7%
Research & Development5.04M7.3M9.29M9.84M15.9M
Selling, General & Admin20.39M21.53M13.29M13.79M16.98M
Operating Expenses55.15M17.98M25.55M61.78M30.77M
Depreciation & Amortization4.21M5.22M1.68M1.56M2.2M
EBITDA(48.46M)(13.31M)(23.12M)(59.02M)(47.92M)
EBITDA Margin-2204.6%-1389.2%-1538.5%-3137.4%-1181.7%
Operating Income(53.73M)(18M)(25.14M)(61.04M)(30.58M)
Operating Margin-2444.3%-1878.6%-1672.4%-3245.1%-754.1%
Interest Income00000
Interest Expense209K83K52K84K109K
Other Income / Expenses854K(615K)281K378K(19.64M)
Income Before Tax(52.87M)(18.61M)(24.86M)(60.66M)(50.22M)
Pre-Tax Margin-2405.4%-1942.8%-1653.7%-3225.0%-1238.5%
Income Tax Expense(9.26M)0000
Net Income(64.1M)(72.9M)(27.78M)(60.66M)(50.22M)
Net Margin-2916.2%-7609.8%-1848.4%-3225.0%-1238.5%
EPS (Basic)(14.40)(20.00)(3.75)(4.66)(1.65)
EPS (Diluted)(14.40)(20.00)(3.75)(4.66)(1.65)
Weighted Avg Shares4.45M5.54M7.65M13.07M30.48M
Weighted Avg Shares (Diluted)4.45M5.54M7.65M13.07M30.48M

Insight Molecular Diagnostics Inc.

NASDAQ:IMDX

Intrinsic Alpha fair value

Locked

Current Price

$1.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.